Postpartum Hemorrhage Clinical Trial
Official title:
Comparison of Condom-Loaded Foley's Catheter Versus Bakri Balloon for Treatment of Primary Postpartum Hemorrhage: A Randomized Controlled Trial
Postpartum hemorrhage (PPH) is responsible for around 25% of maternal mortality worldwide
reaching as high as 60% in some countries.PPH can also be a cause of long-term severe
morbidity, and approximately 12% of women who survive PPH will have severe anemia.
Postpartum hemorrhage has been defined as blood loss in excess of 500 ml in a vaginal birth
and in excess of 1 L in a cesarean delivery.For clinical purposes, any blood loss that has
the potential to produce hemodynamic instability should be considered a PPH. However,
clinical estimates of blood loss are often inaccurate. Primary (immediate) PPH occurs within
the first 24 hours after delivery and approximately 70% of these cases are due to uterine
atony. Furthermore, uterine tony is defined as the failure of the uterus to contract
adequately after the child is born.
Guidelines for the management of postpartum hemorrhage (PPH) involve a stepwise approach
including the exclusion of retained products of conception and genital tract trauma. Uterine
atony, which is the most common cause, the management of uterine atony is an established
stepwise protocol that in many international guidelines.
Uterine massage is recommended for the treatment of PPH. Initiate uterine massages soon as
excessive bleeding/uterine atony is identified. Intravenous oxytocin alone still is the
recommended uterotonic drug for the treatment of PPH.
If intravenous oxytocin is unavailable or if the bleeding does not respond to oxytocin,
intravenous ergometrine, oxytocin-ergometrine fixed dose or a prostaglandin drug (including
sublingual misoprostol, 600 mcg) should be given. The use of intrauterine balloon tamponade
is recommended for the treatment of primary PPH due to uterine atony in women who do not
respond to uterotonics or if uterotonics are not available.
Since 1983, when Goldrath published evidence that inserting a Foley catheter in the uterus
and inflating it with water could achieve tamponade, case series and other studies have
suggested that various uterine balloon tamponade(UBT) devices may be effective in treating
PPH. The studies used various types of UBT devices, including a condom catheter, a Foley
catheter, the Sengstaken-Blakemore Esophageal Tube, the Rusch Balloon, and the Bakri Uterine
Balloon. In 2007, a systematic review of treatment options for PPH found that 84% success
rate of UBT does not significantly vary from surgical treatment outcomes.The World Health
Organization (WHO), the International Federation of Gynecology and Obstetrics (FIGO), the
American College of Obstetricians and Gynecologists(ACOG), the Royal College of Obstetricians
and Gynecologists(RCOG), and the International Confederation of Midwives (ICM) recognize
balloon tamponade as a method that could significantly improve the management intractable
PPH, especially in low-resource areas.
In 2012, WHO updated the guidelines for the management of PPH and retained placenta to
include: "The use of intrauterine balloon tamponade is recommended for the treatment of PPH
due to uterine atony. This recommendation is now stronger than the previous guidelines. It
can be used for women who do not respond to uterotonics or if uterotonics are not available.
This procedure potentially can avoid surgery and is appropriate while awaiting transfer to a
higher-level facility".Furthermore, FIGO included UBT as a recommended second-line
intervention for the treatment of PPH in their updated guidelines issued in 2012.
Bakri first published the concept of intrauterine balloon technology in the management of
hemorrhage secondary to placenta praevia-accreta during caesarean section with or without
bilateral hypo gastric arterial ligation.In 2006, the ACOG Practice Bulletin, published by
the American College of Obstetricians and Gynecologists, made mention of the Bakri postpartum
balloon for its specifically tailored design that enables conservative management of uterine
bleeding in cases of uterine atony and other causes of PPH.
The idea of using a condom as a balloon tamponade was first generated and evaluated in
Bangladesh by Sayeba Akhter to fill a need and in response to the high cost of commercially
available UBT devices.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03434444 -
In Vitro Optimization of Oxytocin-induced Myometrial Contractility by Propranolol
|
N/A | |
Terminated |
NCT01980173 -
Medico-economic Comparison of Postpartum Hemorrhage Management Using the Bakri Balloon and Standard Care
|
N/A | |
Not yet recruiting |
NCT06033170 -
Celox™ PPH for Reaching Haemostasis in Patients With Postpartum Hemorrhage
|
N/A | |
Completed |
NCT02163616 -
Treatment of Postpartum Hemorrhage With Misoprostol: Fever Study
|
Phase 3 | |
Not yet recruiting |
NCT02319707 -
Management of the Third Stage of Labor
|
Phase 3 | |
Recruiting |
NCT01600612 -
Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial
|
N/A | |
Completed |
NCT02079558 -
Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section
|
Phase 2 | |
Withdrawn |
NCT01108302 -
Effectiveness, Safety and Feasibility of Auxiliary Nurse Midwives' (ANM) Use of Oxytocin in Uniject™ to Prevent Postpartum Hemorrhage in India
|
N/A | |
Completed |
NCT00097123 -
RCT of Misoprostol for Postpartum Hemorrhage in India
|
N/A | |
Completed |
NCT02883673 -
Safety and Effectiveness of the Jada System in Treating Primary Postpartum Hemorrhage
|
N/A | |
Completed |
NCT02542813 -
Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers
|
Phase 1 | |
Completed |
NCT04201665 -
EMG for Uterotonic Efficiency Estimation
|
N/A | |
Terminated |
NCT03246919 -
Ideal Time of Oxytocin Infusion During Cesarean Section
|
Phase 4 | |
Not yet recruiting |
NCT05501106 -
Reducing Postpartum Hemorrhage After Vaginal Delivery
|
N/A | |
Completed |
NCT05429580 -
Prophylactic Tranexamic Acid Use After Vaginal Delivery
|
N/A | |
Terminated |
NCT03064152 -
Rotational Thromboelastometry for the Transfusion Management of Postpartum Hemorrhage After Vaginal or Cesarean Delivery
|
N/A | |
Recruiting |
NCT05382403 -
Novel Vacuum-Induced Hemorrhage Control for Postpartum Hemorrhage
|
N/A | |
Not yet recruiting |
NCT02853552 -
Misoprostol as First Aid Measure to Address Excessive Postpartum Bleeding
|
Phase 4 | |
Completed |
NCT02805426 -
Effectiveness of Tranexamic Acid When Used as an Adjunct to Misoprostol for the Treatment of Postpartum Hemorrhage
|
Phase 4 | |
Completed |
NCT02910310 -
Introduction of UBT for PPH Management in Three Countries
|
N/A |